BJMO - volume 15, issue 2, march 2021
A.-S. Vliegen MD, C. Thywissen MD, G. Orye MD, J. Mebis MD, PhD, K. Van Baelen MD, L. Noé MD, L. Vansteelant MD, M. Drijkoningen MD, PhD, N. Van den Rul MD, S. Marquette MD
In clinical practice, the diversity in the surgical management of the axilla after neo-adjuvant chemotherapy (NACT) for node positive patients is huge. Given the morbidity of axillary lymph node dissection (ALND), a trend to perform a less invasive technique is seen in both literature and clinical practice. There are three major techniques: 1) sentinel lymph node biopsy (SLNB), 2) guided removal of lymph nodes that were positive prior to NACT, and 3) Targeted Axillary Dissection (TAD) which is a combination of the previous two techniques. Criteria for patients eligible for these techniques vary widely and oncological safety cannot always be guaranteed. With this report, we aim to introduce TAD in a safe way into the clinical practice.
(BELG J MED ONCOL 2021;15(2):69-74)Read more
BJMO - volume 15, issue 1, january 2021
F. Derouane MD, F.P. Duhoux MD, PhD, K. Punie MD
Hormone-receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer accounts for 65% of all metastatic breast cancer (MBC) cases. With the advent of CDK4/6 inhibitors, single-agent endocrine therapy (ET) is no longer the only first-line systemic treatment option for the vast majority of patients presenting without visceral crisis. Other endocrine-based treatment options are emerging in further lines, with the goal to delay the administration of chemotherapy as long as possible. The optimal sequence of treatment is unknown. We here present a review of the available treatments and propose a treatment algorithm taking into account the latest therapeutic developments.
(BELG J MED ONCOL 2021;15(1):20-33)Read more
BJMO - volume 14, issue 7, november 2020
A. Awada MD, PhD, D. Taylor MD, E. de Azambuja MD, PhD, E. Naert MD, FP. Duhoux MD, PhD, H. Denys MD, PhD, H. Wildiers MD, PhD, K. Punie MD, M. Ignatiadis MD, PhD, M. Rediti MD
Chemotherapy has represented the main treatment option for patients with advanced triple-negative breast cancer for a long time. However, due to our better understanding of tumour biology, recent clinical trials led to a change in the treatment paradigm of this disease, identifying clinically relevant subgroups with different therapeutic options. Both clinical and biological factors have become relevant and need to be considered in the treatment decision algorithm of this heterogeneous disease.
(BELG J MED ONCOL 2020;14(7):333-38)Read more
BJMO - volume 14, issue 2, march 2020
A. Verbiest MD, B. Beuselinck MD, PhD, B. Delafontaine MD, C. De Backer MD, C. Gennigens MD, C. Vulsteke MD, PhD, G. Pelgrims MD, G. Van Lancker MD, L. D’Hondt MD, PhD, M. Strijbos MD, PhD, N. Martínez Chanzá MD, On behalf of the BSMO Uro-Oncology Task Force Group , P. Debruyne MD, PhD, S. Rottey MD, PhD, T. Gil MD
The management of recurrent or metastatic renal cell carcinoma is evolving fast, with new therapeutic options becoming available that may improve the outcome of patients. In this paper, recent evolutions are discussed and recommendations are made regarding the management of renal cell carcinoma in a Belgian context.
(BELG J MED ONCOL 2020;14(2):56–70)Read more
BJMO - volume 13, issue 7, november 2019
A. Dendooven MD, PhD, A. Hébrant PhD, A. Van den Bruel MD, A. Vanderstichele MD, PhD, B. Decallonne MD, PhD, B. Maes MD, PhD, B. Weynand MD, PhD, C. Dooms MD, PhD, C. Van den Broecke MD, D. Creytens MD, PhD, E. Govaerts MD, E. Hauben MD, PhD, E. Van Valckenborgh PhD, E. Wauters MD, PhD, F. Dedeurwaerdere MD, G. Costante MD, G. Floris MD, PhD, G. Martens MD, PhD, G. Raicevic PhD, H. Denys MD, PhD, HA. Poirel MD, PhD, I. Salmon MD, PhD, I. Van den Berghe MD, J. De Grève MD, PhD, J. Kerger MD, PhD, J. Van den Oord MD, PhD, J. Van der Meulen PhD, J.P. Machiels MD, PhD, K. Punie MD, K. Van de Vijver MD, PhD, K. Vandecasteele MD, PhD, K. Vermaelen MD, PhD, L. Brochez MD, PhD, L. Ferdinande MD, PhD, L. Lapeire MD, PhD, L. Van de Voorde MD, L. Vanwalleghem MD, M. Garmyn MD, PhD, M. Lammens MD, PhD, M. Remmelink MD, PhD, M. Van den Bulcke PhD, M.C. Burlacu MD, N. D’Haene MD, PhD, O. Kholmanskikh Van Criekingen MD, PhD, P. De Paepe MD, PhD, P. Lefesvre MD, PhD, P. Neven MD, PhD, P. Pauwels MD, PhD, R. De Pauwn MD, R. Forsyth MD, PhD, R. Salgado MD, PhD, R. Sciot MD, PhD, S. Rottey MD, PhD, S. Tejpar MD, PhD, T. Boterberg MD, PhD, T. Gevaert MD, PhD, V. Kruse MD, PhD, Y. Lalami MD
In order to advise the Federal Government on the reimbursement of molecular tests related to Personalised Medicine in Oncology, the Commission of Personalised Medicine (ComPerMed), represented by Belgian experts, has developed a methodology to classify molecular testing in oncology. The different molecular tests per cancer type are represented in algorithms and are annotated with a test level reflecting their relevance based on current guidelines, drug approvals and clinical data. The molecular tests are documented with recent literature, guidelines and a brief technical description. This methodology was applied on different solid tumours for which molecular testing is a clear clinical need.
(BELG J MED ONCOL 2019;13(7):286–95)Read more
BJMO - volume 13, issue 6, october 2019
C. Gennigens MD, G. Jerusalem MD, PhD
Soft tissue sarcomas represent 75% of all sarcomas and constitute a group of more than 50 different histological subtypes, with an even greater number of molecular subtypes. Localised STSs are generally treated by surgery followed, or preceded, by radiotherapy and according to criteria linked with the risk of local recurrence. Metastatic STSs are principally treated by systemic treatments such as chemotherapy and targeted drugs. The most important drugs used are doxorubicin, ifosfamide, dacarbazine, gemcitabine/docetaxel, eribulin and trabectedin; but also pazopanib. The place of localised treatments (surgery, radiotherapy, radiofrequency, etc.) in this setting is reserved for oligometastatic disease. A multidisciplinary approach is mandatory, with centralisation of all cases in reference centres, as early as at the time of clinical diagnosis of a suspected sarcoma. This ‘centralised’ approach, for this rare and complex disease, has an impact on the oncologic outcomes (quality of resection and overall survival) of patients.
(BELG J MED ONCOL 2019;13(6): 227–233)Read more
BJMO - volume 13, issue 3, may 2019
N. Mottet MD, PhD
Prostate cancer is the third cause of death in developed countries, suggesting a role for systematic screening. However, no country has considered this policy yet. On the contrary, an individual early diagnostic process based on a risk adapted strategy is now considered. In an informed patient with at least fifteen years of life expectancy, the process starts at 45 years of age in a man at risk. Otherwise, it starts at 50 years of age. While already based on a prostate-specific antigen test and a digital rectal examination, the MRI as well as risk calculators or biological tests might be helpful to avoid unnecessary biopsy. However, it must be remembered that finding a tumour does not mean a systematic treatment.
(BELG J MED ONCOL 2019;13(3):93–97)Read more